Dermatomyositis treatment market remains fragmented as Octapharma leads

By AI, Created 5:31 PM UTC, May 18, 2026, /AGP/ – A new Business Research Company report says Octapharma led global dermatomyositis treatment sales in 2024 with 6% market share, while the top 10 players together held 23% of revenue. The report points to selective complement inhibitors, targeted biologics and personalized care tools as the main competitive battlegrounds in a market shaped by rare-disease drug development barriers.

Why it matters: - Dermatomyositis is a rare autoimmune disease, so drug development depends on orphan-drug pathways, small patient populations and strong clinical evidence. - The market’s split across many players suggests no single company has dominant control over treatment strategy or pricing power. - New targeted therapies could improve outcomes by reducing reliance on broad immunosuppression.

What happened: - The Business Research Company published a 2026 market report on dermatomyositis treatment competition. - Octapharma led global sales in 2024 with a 6% market share. - The top 10 companies accounted for 23% of total market revenue in 2024. - The report identifies a mix of global pharmaceutical companies and specialized immunology and rare-disease developers as the main competitors.

The details: - Octapharma’s immunotherapy and plasma-derived therapeutics division supplies immunoglobulin therapies, plasma protein treatments and supportive biologic solutions used in autoimmune and inflammatory care. - Other major companies named in the market include CSL Limited, Grifols, Pfizer, Takeda Pharmaceutical Company, Kedrion Biopharma, Novartis, Roche, Sanofi, AbbVie, Johnson & Johnson, Amgen, GSK, Mallinckrodt, Biotest, Bristol Myers Squibb, Zydus Group, Sun Pharma, Dr. Reddy’s, Cipla, Teva, Merck, Zydus Lifesciences, Aurobindo Pharma and Lupin. - The report says market concentration is moderate because of clinical trial requirements, orphan-drug designation, complex immunology-based development and the need to prove safety and efficacy. - The leading players listed by share are Octapharma at 6%, CSL Limited at 5%, Grifols at 3%, Pfizer at 3%, Takeda at 1%, Kedrion Biopharma at 1%, Novartis at 1%, Roche at 1%, Sanofi at 0.5% and AbbVie at 0.4%. - Major raw material suppliers named in the report include Pfizer, Roche Holding, Novartis, Sanofi, Bristol Myers Squibb, AbbVie, Merck, AstraZeneca, GSK, Eli Lilly, Amgen, Biogen, Takeda, Bayer, Boehringer Ingelheim, Regeneron, UCB, CSL Behring, Vertex, Horizon Therapeutics, Kyowa Kirin, Daiichi Sankyo, Astellas, Ipsen and Sandoz Group. - Major wholesalers and distributors listed include McKesson, Cardinal Health, Cencora, Medipal Holdings, Owens & Minor, Sinopharm, Shanghai Pharmaceuticals, Zuellig Pharma, Phoenix Pharmahandel, Alliance Healthcare, Uniphar, Movianto, H. D. Smith, Morris & Dickson, Anda, CuraScript SD, Walgreens Boots Alliance, Medline, Henry Schein and DHL Supply Chain. - Major end users named in the report include Quest Diagnostics, Apollo Hospitals, Fortis Healthcare, Medanta, Mount Sinai Health System, Kaiser Permanente and Cleveland Clinic Abu Dhabi. - The report says companies are leaning on advanced therapies, targeted treatments, modernized care infrastructure and AI-driven biomarker analytics to improve diagnosis, monitoring and personalized care. - The report also lists selective complement pathway inhibitors as a key trend in the market. - In February 2025, NovelMed Therapeutics received FDA clearance to start a Phase II trial of Ruxoprubart (NM8074), a selective alternative complement pathway inhibitor targeting Factor Bb.

Between the lines: - The competitive focus is shifting toward therapies that modulate the immune system more precisely instead of suppressing it broadly. - That could give an edge to companies that can pair biologic innovation with regulatory progress in rare disease. - The report’s supplier and distributor lists show the market depends on a broad commercial chain, not just drug developers.

What’s next: - The report expects strategic collaborations, drug development innovation and regional expansion to shape competitive positioning. - Companies are likely to keep pushing personalized treatment protocols and biomarker-based care as the market evolves. - More clinical activity around complement inhibitors could widen the pipeline of targeted dermatomyositis options.

The bottom line: - Dermatomyositis treatment remains a small, fragmented market, but competition is intensifying around targeted immunology and precision medicine.